SI-BONE Announces Launch of Public Offering of Common Stock
04 Maio 2023 - 5:09PM
SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to
solving musculoskeletal disorders of the sacropelvic anatomy, today
announced that it has commenced an underwritten public offering of
3,775,000 shares of its common stock. Of the shares of common stock
being offered, 3,502,247 shares are being offered by SI-BONE and
272,753 shares are being offered by a selling stockholder. In
addition, SI-BONE expects to grant the underwriters a 30-day option
to purchase up to an additional 566,250 shares of the company’s
common stock on the same terms and conditions. The offering is
subject to market conditions, and there can be no assurance as to
whether or when the offering may be completed or as to the actual
size or terms of the offering.
BofA Securities, Morgan Stanley, and Jefferies are acting as
joint book-running managers. Canaccord Genuity and Cantor are
acting as co-managers.
A shelf registration statement relating to the shares being sold
in this offering was filed with the U.S. Securities and Exchange
Commission on May 4, 2023 and became effective automatically upon
filing. The offering will be made only by means of a prospectus
supplement and accompanying prospectus. A preliminary prospectus
supplement and accompanying prospectus relating to the offering
will be filed with the SEC and will be available for free
on the SEC’s website located at http://www.sec.gov. When
available, electronic copies of the preliminary prospectus
supplement and accompanying prospectus relating to the proposed
public offering may be obtained: from BofA Securities,
NC1-022-02-25, 201 North Tryon Street, Charlotte, NC 28255-0001,
Attn: Prospectus Department or email at
dg.prospectus_requests@bofa.com; from Morgan Stanley & Co. LLC,
Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New
York, New York 10014; or from Jefferies, by mail at Jefferies LLC,
Attention: Equity Syndicate Prospectus Department, 520 Madison
Avenue, New York, NY 10022, or by telephone at 877-547-6340 or
877-821-7388, or by email at
prospectus_department@jefferies.com.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy, nor shall there be any sale of
these securities in any state or jurisdiction in which such offer,
solicitation, or sale would be unlawful prior to registration or
qualification under the securities laws of any such state or
jurisdiction.
About SI-BONESI-BONE is a medical device
company dedicated to solving musculoskeletal disorders of the
sacropelvic anatomy.
Forward-Looking StatementsThis press release
contains forward-looking statements, including statements relating
to SI-BONE’s expectations regarding the proposed public offering.
These statements are subject to significant risks and uncertainties
and actual results could differ materially from those
projected. SI-BONE cautions investors not to place undue
reliance on the forward-looking statements contained in this
release. These risks and uncertainties include, without limitation,
risks and uncertainties related to market conditions, the risk that
the proposed public offering will not be consummated on the terms
or in the amounts contemplated or otherwise, and the satisfaction
of customary closing conditions related to the proposed public
offering. Risks and uncertainties relating to SI-BONE and
its business can be found in the “Risk Factors” section of
SI-BONE’s Form 10-Q for the quarter ended March 31, 2023,
filed with the SEC on May 2, 2023, and in the
preliminary prospectus related to the proposed public offering
filed or to be filed with the SEC on May 4,
2023. SI-BONE undertakes no duty or obligation to update
any forward-looking statements contained in this release as a
result of new information, future events or changes in SI-BONE’s
expectations, except as required by law.
Investor Contact:Anshul MaheshwariChief
Financial Officerinvestors@SI-BONE.com
Marissa BychPrincipal, Gilmartin
Groupmarissa@gilmartinir.com
SI BONE (NASDAQ:SIBN)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
SI BONE (NASDAQ:SIBN)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024